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Abstract
Background: Simvastatin is commonly prescribed for hypercholesterolemia to reduce vascular risk in patients. Some
of these patients have dementia with cognitive defects of several domains. Although protective effects seem to be
present, there is emerging evidence that statins cause cognitive impairment.
The role of cholesterol in cognitive function is complex. This is reflected in the effects that statins show on cognition
functions. The reduction in cholesterol levels seen with statins is effective in improving learning and memory in some
patients. However, there is emerging evidence that statins may worsen cognitive function. Similarly, there are major
concerns over whether statins alleviate or worsen cognitive problems. The correlation between cholesterol levels and
cognitive function is still controversial, mainly due to a lack of robust evidence.
Case presentation: We report the cases of two Asian patients who developed cognitive deficits after starting
simvastatin. A 32-year-old man and a 54-year-old woman developed different but clear cognitive deficits that
reversed after stopping simvastatin.
Conclusions: The possibility of new-onset cognitive dysfunction and the deterioration of existing cognitive
deficits should be considered when prescribing simvastatin to patients.
Keywords: Simvastatin, Cognitive deficits, Memory loss
Background
Simvastatin is a statin belonging to the 3-hydroxy-3-meth-
ylglutaryl coenzyme A (HMG-CoA) reductase inhibitors
that lower cholesterol levels, particularly low-density lipo-
protein (LDL) cholesterol and triglycerides. It increases
high-density lipoprotein (HDL) cholesterol. Statins gener-
ally have minimal adverse effects, with the common side
effects being myopathies, effects on liver enzymes, diar-
rhea, and, rarely, rhabdomyolysis [1]. Several case reports
and case series have suggested a potential association be-
tween statins and cognitive impairment [2].
With the increased diagnosis of hypercholesterolemia,
the prescription of statins has also increased. Because
cholesterol is heavily implicated as a causative factor in
the formation of amyloid plaques, a reduction in choles-
terol formation is postulated to slow plaque formation [3].
Statins are also reported to possess anti-inflammatory and
anti-oxidant properties. There are several studies and
meta-analyses [3] confirming the benefits of statin use on
cognitive impairment.
Within the population receiving statins, there is a high
proportion with memory loss and associated cognitive
symptoms owing to the strong correlation of vascular
risk factors, like diabetes and hypercholesterolemia, with
vascular and Alzheimer’s dementia. Statins are used to
control vascular risk factors that may contribute to de-
mentia, and there is emerging evidence that statins may
play a protective role in improving memory problems in
dementia [4, 5]. However, there is also increasing con-
cern that statins may be a causative factor for cognitive
problems, mainly memory problems [2], although this
has not yet been reported as a side effect in the British
National Formulary.
The postulation that statins can cause cognitive de-
cline is based on the fact that lipophilic statins like ator-
vastatin and simvastatin show increased crossing of the
blood–brain barrier compared to hydrophilic statins (for
example, pravastatin and rosuvastatin). Two possible
mechanisms are proposed: (1) the reduced availability of
cholesterol caused by statins might impair the integrity
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of the neuronal and glial cell membrane, resulting in slo-
wed conduction of neuronal impulses [6]; and (2) the re-
duced re-myelination and reduction in coenzyme Q10
levels impairs mitochondrial function and may lead to
an increase in oxidative stress [7, 8]. However, in a study
investigating the long-term effects of treatment with
pravastatin and atorvastatin in adult rats, pravastatin
tended to impair learning, implying an impact on working
memory and object recognition memory that was revers-
ible on discontinuation, whereas atorvastatin did not
impair either task. This model contradicts the postulated
mechanism of lipophilic statins causing more cognitive
impairment because pravastatin is hydrophilic and atorva-
statin is lipophilic [9]. Two randomized control trials on
simvastatin [10] and pravastatin [11], which included a
large number of patients, as well as a study conducted in
Australia [12] did not identify a relationship between sta-
tin usage and cognitive decline. However, there are pub-
lished case reports on statins causing memory loss [13].
In a study of 60 patients who had memory loss associated
with statins, 36 patients received simvastatin, 23 atorva-
statin, and 1 pravastatin [13]. About 50 % of patients
showed cognitive adverse effects within 2 months of ther-
apy. A problem with this study, as well as most other case
reports, is the lack of formal cognitive test results in the pa-
tients who developed cognitive changes. No specific mem-
ory test results were documented in any of the 60 reports.
Four reports documented tests such as computed tomog-
raphy, magnetic resonance imaging (MRI), intelligence
quotient (IQ), and an unidentified cognitive test. Test
results were normal for three of the four patients; MRI
results were unknown for one patient [13]. In a randomized
trial with healthy adults, simvastatin was associated with
decreased performance on some neuropsychological tests
compared with the placebo [14]. A survey conducted in
171 patients on statins reported that cognitive problems
associated with statins have variable onset and recovery
courses, and that there is a clear relationship with the po-
tency, resulting in a significant negative impact on quality
of life [15]. In 2012, the United States Food and Drug
Administration (FDA) changed labeling for statins, advising
of the possibility of cognitive impairment and further
adding to the concerns regarding cognitive decline [16].
We report the cases of two patients who reported
memory loss and associated cognitive deficits after
starting simvastatin and recovered following discon-
tinuation. We did formal cognitive testing as well as
brain imaging in both patients, which helps to rectify
the lack of proper neuropsychiatric assessments in
existing case studies.
Case presentation
Our first patient was a 32-year-old Asian man with bipolar
affective disorder who was prescribed 20 mg of simvastatin
for hypercholesterolemia. He complained of forgetfulness
resulting in significant losses to his business one month
after initiation of simvastatin. He had impaired recall and
memory. He did not complain of any disturbances in his
memory prior to starting simvastatin, despite being known
to the services for several years. The collateral history from
his family confirmed that there had been significant, no-
ticeable impairment related to short-term memory that led
him to forget some major business transactions he had
carried out. History from our patient and his family was
obtained to rule out any possible contributory factors for
his symptoms. Our patient did not have any family history
of hypercholesterolemia. He had no features to suggest any
vascular events in the preceding months that may have
contributed to the fairly rapid development of cognitive
dysfunction. Our patient had been stable in his mental
state for more than 1 year at the time he developed cogni-
tive symptoms.
Our patient did not have any abnormalities in an
examination of his central nervous system and an MRI
yielded normal results. Results from biochemical testing
carried out to rule out possible contributory factors, in-
cluding lipid profiles, were normal. His memory, as re-
ported by our patient as well as his relatives, improved
significantly after simvastatin was stopped. Although im-
provements were seen in his short-term recall 3 months
after stopping simvastatin, the improvement was not sig-
nificant on neuropsychological testing. The changes in
the Montreal Cognitive Assessment (MOCA) scale, Mini
Mental State Examination (MMSE), and memory compo-
nent of Neuropsychiatry Unit Cognitive Assessment Tool
(NUCOG) are shown in Table 1. Although improvements
were observed in his cognitive profile, his cholesterol
levels were uncontrolled because he refused to accept any
form of treatment for hypercholesterolemia.
Our second patient was a 54-year-old Asian woman
diagnosed with treatment-resistant schizophrenia who
developed hypercholesterolemia while on clozapine.
She developed memory impairment and difficulty exe-
cuting day-to-day activities 2 months after starting sim-
vastatin. At the time of presentation, she had had these
symptoms for a year. As in the case of our first patient,
there were no prior complaints of memory symptoms.
Her history was obtained from her husband to rule out
other possible causes for her symptoms. Our patient
did not have any family history of hypercholesterol-
emia. Her mental state had been stable for several years
prior to the development of cognitive symptoms. She
did not have any neurological abnormalities on examin-
ation and her MRI was normal. No abnormalities were
noted in biochemical testing, including her lipid profile.
Her scores on cognitive assessment on simvastatin and
3 months after stopping simvastatin are shown in Table 2.
On initial testing, there was impairment in the domains of
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recall, attention, visuoconstruction, memory, executive
functions and language, which improved after discontinu-
ation of simvastatin. Similar to our first patient, the ob-
served improvement of cognitive functions as reported by
our patient and her family was not reflected on formal
testing. She was initiated on a non-statin lipid-regulating
agent and her cholesterol levels are well controlled.
Two years after discontinuation of simvastatin, both
patients remained free of any cognitive symptoms. A
comparison of scores on cognitive testing of the two pa-
tients, while on simvastatin and after discontinuation, is
shown in Fig. 1.
Discussion
Although there were clear deficits in cognitive functions
in our two patients, the pattern of deficits was different.
Both patients had deficits in memory and recall, while
one patient had deficits in attention, visuoconstruction,
memory, and executive functions as well. Our case series
also replicates the findings of Parker et al., who reported
statin-related problems with memory and learning, as
well as reduced performance in established cognitive
tests, that resolved with discontinuation of statin ther-
apy. The subjective and objective improvement of mem-
ory seen with their patient was similar to that in the two
patients we have reported [17]. An objective improve-
ment was seen in neuropsychological testing at least by
a few points after discontinuing simvastatin. However, a
common feature observed in both patients was that the
observed improvement in cognitive and day-to-day func-
tioning was significantly greater than that reflected on
formal neuropsychological testing. Unfortunately, base-
line neurocognitive assessments prior to the develop-
ment of symptoms were unavailable in both patients
because there had been no indication to carry out formal
testing prior to the complaint.
Our findings are similar to several other case reports
that describe development of memory and cognitive im-
pairment. However, other cognitive deficits were not
mentioned in these reports nor imaging techniques used
to exclude other causes [2, 18]. A survey conducted by
Evans et al. on 171 patients showed that cognitive prob-
lems associated with statins have a variable onset and re-
covery course [15]. However, both our patients
developed symptoms within 2 months of starting ther-
apy and recovered within 3 months of stopping therapy.
Our findings also confirm the finding of Evans et al. that
there is a significant negative impact on the quality of
life [15] because both our patients incurred significant
adverse outcomes owing to cognitive impairment, which
reversed with discontinuation of the statin.
It was difficult to determine if the difference in the
pattern of cognitive deficits between our two patients
was due to the difference in the underlying mental dis-
order (bipolar affective disorder versus schizophrenia).
However, it was clear that the causative factor for the
cognitive deficits was not the underlying mental disorder
because the deficits occurred after starting simvastatin
and reversed with its discontinuation.
Table 2 Neuropsychological test scores during and after
stopping simvastatin
Domain With simvastatin After stopping
simvastatin
Orientation Intact Intact
Attention – Forward digit span 5 7




Long-term memory Intact Intact
Montreal Cognitive Assessment 18/30 21/30
Mini Mental State Examination 28/30 30/30







Table 1 Neuropsychological test scores during and after stopping
simvastatin
Domain With simvastatin After stopping
simvastatin
Orientation Intact Intact
Attention – Forward digit span 6 7
– Reverse digit span 4 6
Concentration (serial sevens) Intact Intact
Registration (5 items) Intact Intact
Recall (5 items) 2/5 4/5
Long-term memory Intact Intact
Montreal Cognitive Assessment 24/30 27/30
Mini Mental State Examination 28/30 28/30
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Conclusions
Both our patients developed significant cognitive changes
following commencement of simvastatin. These cognitive
changes were different between our two patients, indicat-
ing that simvastatin may cause non-specific or global cog-
nitive deficits, as predicted by studies done on statins. It is
also important to note that the observed and perceived
impairment of cognitive deterioration was greater than
that reflected on formal neurological testing in both our
patients. Although both patients had comorbidities, the
clinical history, normal neurological and MRI findings,
and the significant reversal of symptoms with discontinu-
ation of simvastatin implicate simvastatin as the cause of
our patients’ cognitive problems. Although definitive con-
clusions cannot be made, the possibility of new-onset as
well as worsening of existing cognitive symptoms should
be borne in mind when prescribing simvastatin. Further
studies with detailed cognitive assessments on larger
samples of patients are required to determine the exact
pattern of cognitive change.
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